Clareo Health | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Vir Biotechnology, Inc.
With
GlaxoSmithKline
Age
18–69
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
For Part A, participants must be aged 18 years or older at the time of obtaining informed consent
For Parts B and C, participants must be aged between 18 years and 69 years old at the time of obtaining informed consent
Participants who have a positive SARS-CoV-2 test result ≤7 days prior to enrollment and oxygen saturation ≥94% on room air and have COVID-19 symptoms and ≤7 days from onset of symptoms
You may not be if
Currently hospitalized or judged by the investigator as likely to require hospitalization in the next 24 hours
Symptoms consistent with severe COVID-19
Participants who, in the judgement of the investigator are likely to die in the next 7 days.
Severely immunocompromised participants
For Parts A and B, prior receipt of a SARS-CoV-2 vaccine at any time prior to enrollment (vaccination with an authorized or approved SARS-CoV-2 vaccine will not be allowed for 90 days after dosing)
For Parts B and C, conditions that would prohibit receipt of IM injections in the investigator's opinion
For Parts A, B and C, receipt of any vaccine within 48 hours prior to enrollment (vaccination with an authorized or approved SARS-CoV-2 vaccine will not be allowed for 90 days after dosing)
